{"DataElement":{"publicId":"5340947","version":"1","preferredName":"Donor Cell Infusion Administration Type","preferredDefinition":"Text term to identify the category of donor cellular infusion (DCI) administered to an individual usually in the setting of a hematopoietic stem cell transplant (HSCT).","longName":"DCI_ADM_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5340873","version":"1","preferredName":"Donor Cell Infusion Administration","preferredDefinition":"Someone who gives blood or tissue or an organ to be used in another person._The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid._A method of putting fluids, including drugs, into the bloodstream._Performing or possessing executive duties; acting as a supervisor or manager.","longName":"2641792v1.0:2629683v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2641792","version":"1","preferredName":"Donor Cell Infusion","preferredDefinition":"Someone who gives blood or tissue or an organ to be used in another person.:The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.:A method of putting fluids, including drugs, into the bloodstream. Also called intravenous infusion.","longName":"C25168:C12508:C15388","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tissue Donor","conceptCode":"C25168","definition":"Someone who gives blood or tissue or an organ to be used in another person.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Infusion Procedure","conceptCode":"C15388","definition":"Any form of treatment that is introduced into the body via a blood vessel, a muscle, or the spinal cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"312821E2-D78C-4CE8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-23","modifiedBy":"ONEDATA","dateModified":"2007-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2629683","version":"1","preferredName":"Administration","preferredDefinition":"Performing or possessing executive duties; acting as a supervisor or manager.","longName":"C48905","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administration, Management","conceptCode":"C48905","definition":"Performing or possessing executive duties; acting as a supervisor or manager.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E554F30-8157-12B7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-17","endDate":null,"createdBy":"UMLLOADER_TRAPSS","dateCreated":"2007-04-17","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"375CD547-5917-BFE6-E050-BB89AD436459","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"REEVESD","dateModified":"2016-07-11","changeDescription":"Curated to support NCI CCR transplant clinical trial.7.11.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5340892","version":"1","preferredName":"Donor Cellular Infusion Type","preferredDefinition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation._Something distinguishable as an identifiable class based on common qualities.","longName":"DCI_TP","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Donor cell infusion T-regulatory Cells","valueDescription":"T-Lymphocytes Regulatory Donor Cellular Infusion","ValueMeaning":{"publicId":"5340931","version":"1","preferredName":"T-Lymphocytes Regulatory Donor Cellular Infusion","longName":"5340931","preferredDefinition":"CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Lymphocytes, Regulatory","conceptCode":"C0039198","definition":"CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-2293-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-22AC-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion Peripheral Blood Mononuclear Cells","valueDescription":"Peripheral Blood Mononuclear Cell Donor Cellular Infusion","ValueMeaning":{"publicId":"5340932","version":"1","preferredName":"Peripheral Blood Mononuclear Cell Donor Cellular Infusion","longName":"5340932","preferredDefinition":"A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral Blood Mononuclear Cell","conceptCode":"C12954","definition":"A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-22B9-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-22D2-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Other, specify","valueDescription":"Other: PLEASE SPECIFY","ValueMeaning":{"publicId":"5333812","version":"1","preferredName":"Other: PLEASE SPECIFY","longName":"5333812v1.00","preferredDefinition":"A directive to indicate a response not listed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify Other","conceptCode":"C157106","definition":"A directive to indicate a response not listed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36834A90-0046-093D-E050-BB89AD4345E4","latestVersionIndicator":"Yes","beginDate":"2016-06-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-06-30","modifiedBy":"KUMMEROA","dateModified":"2023-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-22E6-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion Fibroblasts","valueDescription":"Fibroblast Donor Cellular Infusion","ValueMeaning":{"publicId":"5340933","version":"1","preferredName":"Fibroblast Donor Cellular Infusion","longName":"5340933","preferredDefinition":"A connective tissue cell that makes and secretes collagen proteins.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibroblast","conceptCode":"C12482","definition":"A connective tissue cell that makes and secretes collagen proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-22F4-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-230D-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion T-lymphocyte Cells","valueDescription":"T-Lymphocyte Donor Cellular Infusion","ValueMeaning":{"publicId":"5340934","version":"1","preferredName":"T-Lymphocyte Donor Cellular Infusion","longName":"5340934","preferredDefinition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-231A-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-2333-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion Natural Killer Cells","valueDescription":"Natural Killer Cell Donor Cellular Infusion","ValueMeaning":{"publicId":"5340935","version":"1","preferredName":"Natural Killer Cell Donor Cellular Infusion","longName":"5340935","preferredDefinition":"A type of immune cell that has granules (small particles) with enzymes that can kill tumor cells or cells infected with a virus. A natural killer cell is a type of white blood cell.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Natural Killer Cell","conceptCode":"C12536","definition":"Natural killer cells are cells that resemble large granular lymphocytes.  They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94.  These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-2340-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-2359-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion Negative Fraction CD34+ Cells","valueDescription":"Negative Fraction CD34+ Antigen Donor Cellular Infusion","ValueMeaning":{"publicId":"5340936","version":"1","preferredName":"Negative Fraction CD34+ Antigen Donor Cellular Infusion","longName":"5340936v1.00","preferredDefinition":"Having a surplus of electrons; having a lower electric potential._A part, a fragment of a whole._An indication that CD34 expression has been detected in a sample._A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negative Charge","conceptCode":"C81173","definition":"Having a surplus of electrons; having a lower electric potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Fraction","conceptCode":"C25514","definition":"A part, a fragment of a whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"CD34 Positive","conceptCode":"C148068","definition":"An indication that CD34 expression has been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-2368-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"KUMMEROA","dateModified":"2023-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-2381-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion Mesenchymal Cells","valueDescription":"Mesenchymal Cell Donor Cellular Infusion","ValueMeaning":{"publicId":"5340937","version":"1","preferredName":"Mesenchymal Cell Donor Cellular Infusion","longName":"5340937","preferredDefinition":"Refers to cells that develop into connective tissue, blood vessels, and lymphatic tissue.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesenchymal","conceptCode":"C25721","definition":"Refers to cells that develop into connective tissue, blood vessels, and lymphatic tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-238F-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-23A8-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion Dendritic Cells","valueDescription":"Dendritic Cell Donor Cellular Infusion","ValueMeaning":{"publicId":"5340938","version":"1","preferredName":"Dendritic Cell Donor Cellular Infusion","longName":"5340938","preferredDefinition":"Immunocompetent cells of the lymphoid and hemopoietic systems and skin. They function morphologically and phenotypically by presenting or processing antigens, thereby stimulating cellular immunity. They represent the most potent antigen-presenting cells and, therefore, play a critical role in the primary T cell immune response.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dendritic Cell","conceptCode":"C12583","definition":"Immunocompetent cells of the lymphoid and hemopoietic systems and skin. They function morphologically and phenotypically by presenting or processing antigens, thereby stimulating cellular immunity. They represent the most potent antigen-presenting cells and, therefore, play a critical role in the primary T cell immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-23B5-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-23CE-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion Virus-specific Cytotoxic Cells","valueDescription":"Virus Specific Cytotoxic Cell Donor Cellular Infusion","ValueMeaning":{"publicId":"5340939","version":"1","preferredName":"Virus Specific Cytotoxic Cell Donor Cellular Infusion","longName":"5340939","preferredDefinition":"Minute infectious agents whose genomes are composed of DNA or RNA, but not both. They are characterized by a lack of independent metabolism and the inability to replicate outside living host cells.: Clearly and explicitly stated.: Having the ability to kill cells.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Virus","conceptCode":"C14283","definition":"An infectious agent which consists of two parts, genetic material and a protein coat. These organisms lack independent metabolism, and they must infect the cells of other types of organisms to reproduce. Most viruses are capable of passing through fine filters that retain bacteria, and are not visible through a light microscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Specified","conceptCode":"C38024","definition":"Clearly and explicitly stated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cytotoxic","conceptCode":"C37893","definition":"Having the ability to kill cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-23DE-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-23F7-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion Lymphocytes","valueDescription":"Lymphocyte Donor Cellular Infusion","ValueMeaning":{"publicId":"5340940","version":"1","preferredName":"Lymphocyte Donor Cellular Infusion","longName":"5340940","preferredDefinition":"A type of immune cell that is made in the bone marrow and is found in the blood and in lymph tissue. The two main types of lymphocytes are B lymphocytes and T lymphocytes. B lymphocytes make antibodies, and T lymphocytes help kill tumor cells and help control immune responses. A lymphocyte is a type of white blood cell.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte","conceptCode":"C12535","definition":"White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each); those with characteristics of neither major class are called null cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375DE870-2404-D76D-E050-BB89AD43024C","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375DE870-241D-D76D-E050-BB89AD43024C","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Donor cell infusion CD34 Selected Stem Cell Boost","valueDescription":"CD34 Select Stem Cell Boost Donor Cellular Infusion","ValueMeaning":{"publicId":"5340903","version":"1","preferredName":"CD34 Select Stem Cell Boost Donor Cellular Infusion","longName":"5340903","preferredDefinition":"A measurement of the CD34 expressing cells per unit in a biological specimen.: Relatively undifferentiated cells of the same lineage (family type) that retain the ability to divide throughout postnatal life to reproduce themselves and to give rise to other more specialized types of cells to take the place of those that die or are lost. (MeSH): Increase or raise.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CD34 Measurement","conceptCode":"C102260","definition":"The determination of the amount of CD34 expressing cells present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Stem Cell","conceptCode":"C12662","definition":"An unspecialized cell that has the capacity for reproduction through cell division and can be induced to differentiate into a tissue or organ specific cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Boost","conceptCode":"C25438","definition":"Increase or raise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375D7CFE-6CB5-3B52-E050-BB89AD430740","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375D7CFE-6CCE-3B52-E050-BB89AD430740","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5340891","version":"1","preferredName":"Donor Cellular Infusion Type","preferredDefinition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.:Something distinguishable as an identifiable class based on common qualities.","longName":"C77273:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375D7CFE-6BF8-3B52-E050-BB89AD430740","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Application","id":"375D7CFE-6C09-3B52-E050-BB89AD430740","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"KUMMEROA","dateModified":"2023-10-02","changeDescription":null,"administrativeNotes":"2023.10.2 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Donor cell infusion type","type":"Preferred Question Text","description":"Donor cell infusion type","url":null,"context":"CCR"}],"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"375D4B08-68DF-010D-E050-BB89AD4312C9","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-11","modifiedBy":"REEVESD","dateModified":"2017-02-11","changeDescription":"Curated to support NCI CCR transplant study.7.11.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}